Middle East & Africa Epilepsy Market Forecast to 2030
Middle East & Africa Epilepsy Market Forecast to 2030 – Regional Analysis – by Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First Generation Drugs, Second Generation Drugs, and Third Generation Drugs), Age Group (Adult and Children), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Gene Therapy as Promising Treatment Approach Bolsters Middle East & Africa Epilepsy Market
Gene therapies are being explored as potential treatment options for certain genetic epilepsies. This innovative approach is aimed at treating diseases by modifying or manipulating the genetic makeup of cells. The fundamental principle of gene therapy is to correct or replace faulty genes that contribute to the development or progression of a particular condition. Since epileptic seizures are caused by excessive brain cell activity (neurons) in particular parts of the organ, targeting these neurons and turning them off could help prevent seizures. Two standard gene therapy techniques that can be employed to design an epilepsy treatment are gene addition and gene editing. Gene addition involves adding genetic material to an individual’s cells to balance a missing or abnormal gene, while gene editing involves treating genetic epilepsy by directly modifying an individual’s gene. By targeting specific genes associated with epilepsy and manipulating cellular genetic material, gene therapy can help restore normal cellular function and inhibit seizure generation.
Examining the genetic causes of a condition allows healthcare providers to offer more personalized and targeted treatment approaches. In cases involving heritable mutations, this knowledge aids in understanding the risks for affected families and facilitates genetic counseling, followed by informed decision-making. Ongoing advancements in the identification of genetic factors causing epilepsy to play a crucial role in guiding the medical care and management of affected individuals. Next-generation sequencing has largely driven significant progress in the field of genetics. This high-throughput genetic sequencing technique enables a faster and more comprehensive analysis of DNA, thereby aiding the identification of genetic causes of conditions such as epilepsy.
The continued progress in genetic research holds the potential to improve the care and support provided to individuals with epilepsy and their families. By targeting genes associated with ion channels, neurotransmitter receptors, or cellular signaling pathways, researchers can investigate how alterations in these genes contribute to epileptogenesis.
Although gene therapy for epilepsy is still in the early stages of development, preclinical studies in animal models have shown promising results. Animal models with specific epilepsy-related genetic mutations have been treated using gene therapy approaches, resulting in reduced seizure frequency and improved seizure control. In December 2023, UCL Queen Square Institute of Neurology researchers developed a new gene therapy to cure a devastating form of childhood epilepsy, which has been shown to notably reduce seizures in mice. They assessed a gene therapy based on the overexpression of a potassium channel that controls neuronal excitability in a mouse model with focal cortical dysplasia in the frontal lobe. The researchers injected an engineered potassium channel gene termed EKC into the affected frontal lobe of epileptic mice. They employed a virus lacking replicability as a vector to carry the potassium channel gene. The researchers found that gene therapy lowered seizures by an average of 87% compared to the control group without altering the mouse’s memory or behavior. Taking into account the unmet needs in epilepsy therapeutics, it can be utilized to treat children who are severely affected by uncontrolled seizures.
Many gene therapy trials for the treatment of epilepsy are currently underway or in the planning stages. The purpose of these trials is to estimate the safety and effectiveness of gene therapies in human patients with specific genetic forms of epilepsy. It is an AAV-based gene therapy that has the potential to enhance the quality of life for people with drug-resistant focal epilepsy, for which no effective treatment is available currently. The therapy candidate CG01 uses a gene therapy vector to deliver a combination of neuropeptide Y and its receptor Y2 directly to the area of the brain that triggers epileptic seizures.
Thus, gene therapy is likely to serve as a promising new trend in the epilepsy market in the coming years.
Middle East & Africa Epilepsy Market Overview
The epilepsy market in the MEA is further segmented into the UAE, Saudi Arabia, South Africa, and the Rest of MEA. The median prevalence of epilepsy in MEA countries is 7 per 1,000 persons. The most common risk factors that were found to be associated with increased risk of epilepsy development include consanguinity, family history of epilepsy, and a history of perinatal infections.
Middle East & Africa Epilepsy Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Epilepsy Market Segmentation
The Middle East & Africa epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.
Based on type, the Middle East & Africa epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.
In terms of route of administration, the Middle East & Africa epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.
By treatment type, the Middle East & Africa epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third-generation drugs segment held the largest market share in 2022.
Based on age group, the Middle East & Africa epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.
In terms of distribution channel, the Middle East & Africa epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.
By country, the Middle East & Africa epilepsy market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa epilepsy market share in 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Middle East & Africa epilepsy market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According toThe Research Team’ research, the Middle East & Africa epilepsy market was valued at US$ 456.34 million in 2022 and is expected to reach US$ 568.00 million by 2030, registering a CAGR of 2.8% from 2022 to 2030. Rising prevalence of epilepsy and surge in awareness programs conducted by organizations are among the critical factors attributed to drive the Middle East & Africa epilepsy market growth.
Epilepsy, also termed a seizure disorder, is a chronic disease of the brain. It is characterized by recurrent seizures, which are brief episodes of involuntary movement of a part of the body or the entire body. Seizures can alter sensations, behaviors, awareness, and muscle movements. Epilepsy may occur due to a genetic disorder or an acquired brain injury, such as trauma or stroke. According to data published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly 50 million people across the world. Moreover, 4-10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. This number can reach as high as 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries, and the elevated risk of endemic conditions such as neurocysticercosis or malaria. The WHO also states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications. Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives market growth.
On the contrary, recall of products hampers the growth of Middle East & Africa epilepsy market.
Based on type, the Middle East & Africa epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held 52.6% market share in 2022, amassing US$ 240.17 million. It is projected to garner US$ 307.29 million by 2030 to register 3.1% CAGR during 2022-2030.
In terms of route of administration, the Middle East & Africa epilepsy market is categorized into oral, parenteral, and others. The oral segment held 67.8% share of Middle East & Africa epilepsy market in 2022, amassing US$ 309.38 million. It is anticipated to garner US$ 399.79 million by 2030 to expand at 3.3% CAGR during 2022-2030.
By treatment type, the Middle East & Africa epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held 42.6% share of Middle East & Africa epilepsy market in 2022, amassing US$ 194.40 million. It is projected to garner US$ 250.37 million by 2030 to expand at 3.2% CAGR from 2022 to 2030.
Based on age group, the Middle East & Africa epilepsy market is bifurcated into adult and children. The adult segment held 79.9% share of Middle East & Africa epilepsy market in 2022, amassing US$ 364.49 million. It is predicted to garner US$ 459.12 million by 2030 to expand at 2.9% CAGR between 2022 and 2030.
In terms of distribution channel, the Middle East & Africa epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 51.2% share of Middle East & Africa epilepsy market in 2022, amassing US$ 233.53 million. It is projected to garner US$ 281.33 million by 2030 to expand at 2.4% CAGR from 2022 to 2030.
By country, the Middle East & Africa epilepsy market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 27.7% share of Middle East & Africa epilepsy market in 2022. It was assessed at US$ 126.60 million in 2022 and is likely to hit US$ 147.87 million by 2030, registering a CAGR of 2.0% during 2022-2030.
Key players operating in the Middle East & Africa epilepsy market are Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS, among others.
In May 2023, the biotechnology company Neuro3 Therapeutics (Neuro3), which focuses on finding and creating novel medications to treat illnesses of the central nervous system has signed an exclusive global license and option deal with Lundbeck. The agreement focuses on KCNQ2 ion channel activators, which have been clinically verified as targets for epilepsy treatment. According to clinical research, KCNQ2 channel activation may offer therapeutic alternatives for treating various neurological conditions, such as uncommon forms of epilepsy. The agreement states that Neuro3 will be in charge of developing the two clinical stage and one pre-clinical stage KCNQ2 activator program further through clinical proof-of-concept (PoC). Neuro3 will also obtain a worldwide license for intellectual property related to these products. Lundbeck and Neuro3 may choose to co-develop and co-commercialize after the PoC experiments are finished. Furthermore, Lundbeck has the ability to re-exclusively lease the rights back in specific regions.
In October 2022, Following Pfizer Inc.’s acquisition of Biohaven Pharmaceuticals, Biohaven Pharmaceuticals declared its intention to develop treatments for neurological and neuropsychiatric conditions. The company is concentrating on BHV-7000, an investigational therapy for epilepsy that targets the Kv7 ion pathway. Phase I development of BHV-7000 is in underway for a number of indications.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa epilepsy market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation – Overview
4.1.3.1.2 Gene Modulation – Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference – Overview
4.1.3.1.4 Neuropeptides – Overview
4.1.3.1.5 Engineered Channels – Overview
4.1.3.1.6 Endogenous Channels – Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides – Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Middle East & Africa Epilepsy Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market – Middle East & Africa Analysis
6.1 Middle East & Africa: Epilepsy Market
7. Middle East & Africa Epilepsy Market Analysis – by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Epilepsy Market Analysis – by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Epilepsy Market Analysis – by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
10. Middle East & Africa Epilepsy Market Analysis – by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11. Middle East & Africa Epilepsy Market Analysis – by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12. Middle East & Africa Epilepsy Market – Country Analysis
12.1 Middle East & Africa Epilepsy Market Overview
12.1.1 Middle East & Africa: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 Saudi Arabia: Epilepsy Market Overview
12.1.1.2 Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 Saudi Arabia: Epilepsy Market Breakdown, by Type
12.1.1.2.2 Saudi Arabia: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 Saudi Arabia: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 Saudi Arabia: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 Saudi Arabia: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 South Africa: Epilepsy Market Overview
12.1.1.4 South Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 South Africa: Epilepsy Market Breakdown, by Type
12.1.1.4.2 South Africa: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 South Africa: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 South Africa: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 South Africa: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 United Arab Emirates: Epilepsy Market Overview
12.1.1.6 United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 United Arab Emirates: Epilepsy Market Breakdown, by Type
12.1.1.6.2 United Arab Emirates: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 United Arab Emirates: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 United Arab Emirates: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 United Arab Emirates: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Rest of Middle East & Africa: Epilepsy Market Overview
12.1.1.8 Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Research Team
Table 1. Middle East & Africa Epilepsy Market Segmentation
Table 2. Cell Therapy Approach – An Overview
Table 3. Gene Therapy Approach – An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach – An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
Table 11. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 12. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 13. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 14. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 15. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 16. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 17. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 18. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 19. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 20. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 21. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 22. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 23. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 24. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 25. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 26. Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 27. Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Route of Administration
Table 28. Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Treatment Type
Table 29. Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Age Group
Table 30. Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million) – by Distribution Channel
Table 31. Recent Organic Growth Strategies in Epilepsy Market
Table 32. Recent Inorganic Growth Strategies in the Epilepsy Market
Figure 1. Middle East & Africa Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) – by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) – by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) – by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) – by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) – by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Middle East & Africa: Epilepsy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 26. Middle East & Africa: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 28. South Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 29. United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 30. Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030(US$ Million)
Figure 31. Growth Strategies in Epilepsy Market
The List of Companies – Middle East & Africa Epilepsy Market
o Abbott Laboratories
o Pfizer Inc
o Eisai Co Ltd
o UCB SA
o LivaNova Plc
o Novartis AG
o Medtronic Plc
o GSK Plc
o H. Lundbeck AS
You must be logged in to post a review.
Reviews
There are no reviews yet.